Related Experiment Video
Updated: May 11, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Case Report: Successful Remission With Upadacitinib in Behçet's Syndrome Following a History of PFAPA Syndrome
Hideki Oka1, Shuji Sumitomo1, Daisuke Yamashita2
1Department of Rheumatology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Abstract:
Recent studies have revealed a shared genetic background and pathogenesis between Behçet's syndrome (BS) and periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. This study suggests genetic similarities between recurrent aphthous stomatitis, PFAPA syndrome, and BS and proposes the concept of Behçet's spectrum disorders. An 18-year-old female with a history of PFAPA syndrome who had experienced repeated attacks until puberty visited our hospital complaining of oral ulcers, arthralgia, rash, and abdominal pain that had persisted for 2 weeks. Colonoscopy revealed a deep ulcer in the ileocecal region. Pathological findings showed no evidence suggestive of viral infection, malignancy, or vasculitis, and only nonspecific inflammatory cell infiltration. After ruling out various autoinflammatory diseases through genetic testing, the patient was diagnosed with Behçet's spectrum disorder. The patient was refractory to adalimumab and achieved remission after upadacitinib therapy. Genetic similarities have been reported between PFAPA syndrome and BS, involving genes such as IL-10 and IL-12A. Since the IL-10, IL-12, and IL-23 pathways can be blocked by JAK inhibitors, JAK inhibition therapy may be a potentially effective treatment option for Behçet's syndrome in a patient with a history of PFAPA syndrome.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

